Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down Following Weak Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s share price gapped down before the market opened on Friday following a dissappointing earnings announcement. The stock had previously closed at $23.50, but opened at $21.54. Ultragenyx Pharmaceutical shares last traded at $21.0370, with a volume of 1,032,862 shares.

The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 566.58% and a negative net margin of 85.54%.The business had revenue of $207.00 million for the quarter, compared to the consensus estimate of $199.60 million. During the same period in the previous year, the company posted ($1.39) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% compared to the same quarter last year.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Q4 revenue beat and strong year-over-year growth — Ultragenyx reported $207M in Q4 revenue (up ~25% Y/Y) and 2025 total revenue of $673M, driven by Crysvita and Dojolvi sales, showing commercial momentum that supports the franchise. Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
• Positive Sentiment: Pipeline upside remains a near-term catalyst — management highlighted upcoming potential product launches and an important gene‑therapy data readout that could materially accelerate commercial revenue if successful. Why Is Ultragenyx Stock Sinking Friday?
• Neutral Sentiment: Some analysts still rate RARE favorably — the stock carries an average analyst rating around “Moderate Buy,” which could temper further downside if pipeline readouts stay on track. Ultragenyx Receives Average Rating of “Moderate Buy”
• Negative Sentiment: EPS miss and weaker guidance — Q4 EPS missed estimates (loss of $1.29 vs. -$1.20 expected) and FY2026 revenue guidance ($730M–$760M) came in below Street forecasts, reducing near-term visibility on profitability. Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates
• Negative Sentiment: Cost cuts and layoffs announced — management disclosed a strategic restructuring and ~10% workforce reduction as it pushes to reach profitability by 2027, signaling tougher near-term execution and one-time charges. Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans
• Negative Sentiment: Multiple securities-class-action notices filed — several law firms have announced class actions and investor alerts covering purchases from Aug 3, 2023 to Dec 26, 2025, creating legal overhang and potential liability/management distraction. RARE Investors Have Opportunity to Lead Ultragenyx Securities Fraud Lawsuit
• Negative Sentiment: Street price-target cuts and sell-side concern — reporters note multiple analyst target reductions and growing clinical/pipeline uncertainty, which pressurizes the stock until clearer clinical or commercial milestones are achieved. RARE stock slumps on multiple Wall Street price target slashes, clinical pipeline uncertainty

Analyst Ratings Changes

RARE has been the topic of a number of research reports. Jefferies Financial Group cut their price target on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a report on Tuesday, December 30th. Robert W. Baird cut their target price on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Guggenheim reduced their price target on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Leerink Partners lowered their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Finally, Wells Fargo & Company reduced their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a report on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $72.29.

Insider Activity

In other news, CFO Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $23.56, for a total transaction of $72,117.16. Following the completion of the transaction, the chief financial officer directly owned 88,935 shares in the company, valued at approximately $2,095,308.60. The trade was a 3.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 6,227 shares of company stock valued at $187,126 over the last ninety days. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RARE. Assetmark Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,024 shares during the period. Huntington National Bank lifted its position in Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the last quarter. Danske Bank A S bought a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth approximately $39,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $55,000. Finally, Smartleaf Asset Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares during the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Stock Down 12.7%

The stock has a 50 day moving average price of $26.91 and a two-hundred day moving average price of $29.75. The company has a market cap of $1.98 billion, a P/E ratio of -3.51 and a beta of 0.16.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.